Madeleine Carbonneau

Madeleine Carbonneau

Auto-generated profile, based on publicly available information

Madeleine Carbonneau

Harvard T.H. Chan School of Public Health

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
MCMadeleine Carbonneau
Madeleine Carbonneau
YLYi Li
Yi Li
BPBrenton Prescott
Brenton Prescott
CLChunyu Liu
Chunyu Liu
THTianxiao Huan
Tianxiao Huan
Jiantao MaJiantao Ma
Jiantao Ma
Background: Life's Essential 8 (LE8) is an enhanced metric for cardiovascular health. The interrelations among LE8, biomarkers of aging, and disease risks are unclear. Methods and Results: LE8 score was calculated for 5682 Framingham Heart Study participants. We implemented 4 DNA methylation‐based epigenetic age biomarkers, with older epigenetic age hypothesized to represent faster biological aging, and examined whether these biomarkers mediated the associations between the LE8 score and cardiovascular disease (CVD), CVD‐specific mortality, and all‐cause mortality. We found that a 1 SD increase in the LE8 score was associated with a 35% (95% CI, 27–41; P =1.8E‐15) lower risk of incident CVD, a 36% (95% CI, 24–47; P =7E‐7) lower risk of CVD‐specific mortality, and a 29% (95% CI, 22–35; P =7E‐15) lower risk of all‐cause mortality. These associations were partly mediated by epigenetic age biomarkers, particularly the GrimAge and the DunedinPACE scores. The potential mediation effects by epigenetic age biomarkers tended to be more profound in participants with higher genetic risk for older epigenetic age, compared with those with lower genetic risk. For example, in participants with higher GrimAge polygenic scores (greater than median), the mean proportion of mediation was 39%, 39%, and 78% for the association of the LE8 score with incident CVD, CVD‐specific mortality, and all‐cause mortality, respectively. No significant mediation was observed in participants with lower GrimAge polygenic score. Conclusions: DNA methylation‐based epigenetic age scores mediate the associations between the LE8 score and incident CVD, CVD‐specific mortality, and all‐cause mortality, particularly in individuals with higher genetic predisposition for older epigenetic age.

19 August 2025 in Circulation
Verified
Journal Article
Closed access
MCMadeleine Carbonneau
Madeleine Carbonneau
YLYi Li
Yi Li
YQYishu Qu
Yishu Qu
YZYinan Zheng
Yinan Zheng
AFAlexis Frazier-Wood
Alexis Frazier-Wood
Jiantao MaJiantao Ma
Jiantao Ma
BACKGROUND: The association of overall cardiovascular health (CVH) with changes in DNA methylation (DNAm) has not been well characterized. METHODS: We calculated the American Heart Association’s Life’s Essential 8 score to reflect CVH in 5 cohorts with diverse backgrounds (mean age 54 years, 55% women, and enrollment year ranging from 1989 to 2012). Epigenome-wide association studies (EWAS) for Life’s Essential 8 score were conducted, followed by bioinformatic analyses. DNAm loci significantly associated with Life’s Essential 8 score were used to calculate a CVH DNAm score. We examined the association of the CVH DNAm score with incident cardiovascular disease (CVD), cardiovascular disease–specific mortality, and all-cause mortality. RESULTS: We identified 609 cytosine-phosphate-guanines (CpGs) associated with Life’s Essential 8 score at false discovery rate<0.05 in the discovery analysis and at Bonferroni-corrected P <0.05 in the multicohort replication stage. Most had low to moderate heterogeneity (414 CpGs [68.0%] with heterogeneity <0.2) in replication analysis. Pathway enrichment analyses and a phenome-wide association study search associated these CpGs with inflammatory or autoimmune phenotypes. We observed enrichment for phenotypes in the Epigenome-Wide Association Study Catalog, with 29-fold enrichment for stroke ( P =2.4e−15) and 21-fold for ischemic heart disease ( P =7.4e−38). Two-sample Mendelian randomization (MR) analysis showed significant association between 141 CpGs and ten phenotypes (261 CpG-phenotype pairs) at false discovery rate<0.05. For example, hypomethylation at cg20544516 ( MIR33B [microRNA 33b] and SREBF1 [sterol regulatory element–binding transcription factor 1]) is associated with a lower risk of stroke ( P =8.1e−6). In multivariable prospective analyses, the CVH DNAm score was consistently associated with clinical outcomes across participating cohorts. Per SD increase in the CVH DNAm score, the decrease in risk of incident cardiovascular disease, cardiovascular disease mortality, and all-cause mortality ranged from 19% to 32%, 28% to 40%, and 27% to 45%, respectively. CONCLUSIONS: We identified new DNAm signatures for CVH across diverse cohorts. Our analyses indicate that multiple biological pathways may be relevant to the observed association between CVH and clinical outcomes.

20 November 2024 in medRxiv
Verified
Preprint
Open access
PDF file
MCMadeleine Tapley Carbonneau
Madeleine Tapley Carbonneau
YLYi Li
Yi Li
YQYishu Qu
Yishu Qu
YZYinan Zheng
Yinan Zheng
AFAlexis Frazier-Wood
Alexis Frazier-Wood
Jiantao MaJiantao Ma
Jiantao Ma
Background: The association of overall cardiovascular health (CVH) with changes in DNA methylation (DNAm) has not been well characterized. Methods: We calculated the American Heart Association’s Life’s Essential 8 (LE8) score to reflect CVH in five cohorts with diverse ancestry backgrounds. Epigenome-wide association studies (EWAS) for LE8 score were conducted, followed by bioinformatic analyses. DNAm loci significantly associated with LE8 score were used to calculate a CVH DNAm score. We examined the association of the CVH DNAm score with incident CVD, CVD-specific mortality, and all-cause mortality. Results: We identified 609 CpGs associated with LE8 score at false discovery rate (FDR) < 0.05 in the discovery analysis and at Bonferroni corrected P < 0.05 in the multi-cohort replication stage. Most had low-to-moderate heterogeneity (414 CpGs [68.0%] with I 2 < 0.2) in replication analysis. Pathway enrichment analyses and phenome-wide association study (PheWAS) search associated these CpGs with inflammatory or autoimmune phenotypes. We observed enrichment for phenotypes in the EWAS catalog, with 29-fold enrichment for stroke ( P = 2.4e-15) and 21-fold for ischemic heart disease ( P = 7.4e-38). Two-sample Mendelian randomization (MR) analysis showed significant association between 141 CpGs and ten phenotypes (261 CpG-phenotype pairs) at FDR < 0.05. For example, hypomethylation at cg20544516 ( MIR33B ; SREBF1 ) associated with lower risk of stroke ( P = 8.1e-6). In multivariable prospective analyses, the CVH DNAm score was consistently associated with clinical outcomes across participating cohorts, the reduction in risk of incident CVD, CVD mortality, and all-cause mortality per standard deviation increase in the DNAm score ranged from 19% to 32%, 28% to 40%, and 27% to 45%, respectively. Conclusions: We identified new DNAm signatures for CVH across diverse cohorts. Our analyses indicate that immune response-related pathways may be the key mechanism underpinning the association between CVH and clinical outcomes.

28 June 2026 in bioRxiv
Verified
Preprint
Open access
MCMadeleine Carbonneau
Madeleine Carbonneau
KSKatherine H. Shutta
Katherine H. Shutta
JMJeffrey Miller
Jeffrey Miller
Xiaotao ShenXiaotao Shen
Xiaotao Shen
MSMichael P Snyder
Michael P Snyder
JQJohn Quackenbush
John Quackenbush
A growing body of literature has investigated the relationship between age and biomolecular changes, leading to conclusions that aging occurs in discrete molecular ``waves.'' Data summary tools such as LOESS and sliding window analyses like DE-SWAN are common approaches that have gained acceptance in recent years. We demonstrate via simple simulations that these tools can identify non-linear patterns of aging where they do not exist. Specifically, we show that (i) clustering of molecular trajectories using LOESS can lead to artifactual characteristic patterns of molecular aging, (ii) ``waves'' of aging identified using the combination of LOESS and DE-SWAN in real data are not robust to changes in the underlying age distribution and are not supported by valid permutation testing, and (iii) DE-SWAN alone can generate pronounced "waves'" of nonlinear molecular aging in linear data due to differences in statistical power along the age continuum. Our results specifically challenge the statistical support for discrete aging crests inferred in the literature, but do not rule out nonlinear molecular aging or age-associated transitions that may be detectable using other cohorts and statistical models.